当前位置:首页 - 行情中心 - 百克生物(688276) - 财务分析 - 利润表

百克生物

(688276)

  

流通市值:82.11亿  总市值:82.11亿
流通股本:4.14亿   总股本:4.14亿

利润表

报告期2025-09-302025-06-302025-03-312024-12-31
公司类型通用通用通用通用
一、营业总收入474,442,765.98284,896,170.67162,290,516.781,229,084,097.15
  营业收入474,442,765.98284,896,170.67162,290,516.781,229,084,097.15
二、营业总成本628,977,112.72382,049,170.48167,225,569.52929,411,066.43
  营业成本116,695,814.961,615,318.4823,911,867.74179,178,525.61
  税金及附加5,215,196.723,690,853.411,920,768.349,969,603.18
  销售费用285,454,631.67165,564,616.2673,607,698.35474,960,286.31
  管理费用81,861,124.6257,540,332.930,714,832.48112,929,752.77
  研发费用138,541,423.7293,166,982.1336,858,462.61156,141,989.57
  财务费用1,208,921.09471,067.3211,940-3,769,091.01
  其中:利息费用2,487,560.281,331,702.97558,656.631,518,736.6
  其中:利息收入1,330,901.77977,831.18417,374.554,598,072.1
三、其他经营收益
  加:投资收益-24,572,779.88-15,297,321.86-6,783,077.71-440,272.56
  资产处置收益---2,769.37
  资产减值损失(新)-48,614,287.46-4,343,250.21--39,951,282.53
  信用减值损失(新)-2,397,194.886,727,257.992,708,055.63-6,200,966.72
  其他收益3,397,646.122,101,741.92549,451.794,805,754.67
四、营业利润-226,720,962.84-107,964,571.97-8,460,623.03257,889,032.95
  加:营业外收入23,102,925.468,668,213.565,153,088.564,895,889.02
  减:营业外支出957,609.43309,641.06163,098.617,012,011.05
五、利润总额-204,575,646.81-99,605,999.47-3,470,633.08255,772,910.92
  减:所得税费用-46,325,126.88-26,032,571.43-4,534,908.8623,679,085.19
六、净利润-158,250,519.93-73,573,428.041,064,275.78232,093,825.73
(一)按经营持续性分类
  持续经营净利润-158,250,519.93-73,573,428.041,064,275.78232,093,825.73
(二)按所有权归属分类
  归属于母公司股东的净利润-158,250,519.93-73,573,428.041,064,275.78232,093,825.73
  扣除非经常损益后的净利润-179,726,706.79-82,232,410.99-3,411,965.39229,810,386.8
七、每股收益
  (一)基本每股收益-0.38-0.1800.56
  (二)稀释每股收益-0.38-0.1800.56
八、其他综合收益-9,002,103.61-6,633,894.84-4,619,106.086,594,931.27
  归属于母公司股东的其他综合收益-9,002,103.61-6,633,894.84-4,619,106.086,594,931.27
九、综合收益总额-167,252,623.54-80,207,322.88-3,554,830.3238,688,757
  归属于母公司股东的综合收益总额-167,252,623.54-80,207,322.88-3,554,830.3238,688,757
公告日期2025-10-312025-08-302025-04-212025-04-21
审计意见(境内)标准无保留意见
TOP↑